Cmd in aki and ckd
Reading File
search_medical_text
coronary microvascular dysfunction CMD in acute kidney injury AKI
search_medical_text
coronary microvascular dysfunction CMD in chronic kidney disease CKD
GradeResponse
GradeResponse
The retrieval is sparse on CMD specifically. I'll synthesize a comprehensive answer from my clinical knowledge, supplemented by what was retrieved.
Coronary Microvascular Dysfunction (CMD) in AKI and CKD
Overview
Coronary Microvascular Dysfunction (CMD) refers to functional and/or structural abnormalities of the coronary microvasculature (vessels < 500 µm) that impair myocardial perfusion in the absence of obstructive epicardial coronary artery disease (CAD). Both AKI and CKD create a pro-inflammatory, uremic, hemodynamic milieu that profoundly accelerates CMD.
Pathophysiology of CMD in Kidney Disease
Shared Mechanisms (AKI + CKD)
| Mechanism | Effect on Coronary Microvasculature |
|---|---|
| Systemic inflammation (IL-6, TNF-α, CRP) | Endothelial activation, reduced NO bioavailability, capillary rarefaction |
| Oxidative stress | Peroxynitrite-mediated endothelial injury, impaired vasodilation |
| Sympathetic/RAAS activation | Vasoconstriction, microvascular remodeling |
| Uremic toxins (indoxyl sulfate, p-cresol sulfate) | Endothelial dysfunction, vascular smooth muscle hypertrophy |
| Anemia | Compensatory tachycardia, increased wall stress, microvascular shear stress |
| Fluid overload / hypertension | Increased LV mass, impaired subendocardial perfusion |
CMD in Acute Kidney Injury (AKI)
Specific Mechanisms
- Ischemia-reperfusion injury: AKI triggers systemic release of DAMPs (damage-associated molecular patterns), causing distant organ (including cardiac) microvascular endothelial injury — the cardiorenal syndrome type 3 axis.
- Cytokine storm: Acute elevation of IL-1β, TNF-α directly impairs coronary microvascular tone.
- Volume dysregulation: Rapid fluid shifts alter coronary perfusion pressure and capillary hydrostatic pressures.
- Hemodynamic instability (sepsis-related AKI): Distributive shock causes impaired coronary autoregulation.
Clinical Implications in AKI
- Troponin elevation in AKI is partly driven by CMD-mediated demand ischemia (Type 2 MI pattern)
- CMD contributes to reduced coronary flow reserve (CFR) acutely, potentially reversible if AKI resolves
- Patients with AKI after cardiac surgery (post-cardiotomy AKI) show bidirectional injury — CMD worsens renal perfusion, and AKI worsens CMD
Cardiorenal Syndrome (CRS) Link
| CRS Type | Directionality | CMD Role |
|---|---|---|
| Type 1 | Acute cardiac → AKI | Reduced CO → renal ischemia |
| Type 3 | AKI → Acute cardiac dysfunction | Inflammatory/uremic CMD |
CMD in Chronic Kidney Disease (CKD)
Specific Mechanisms
- Capillary rarefaction: CKD causes structural loss of myocardial microvessels, reducing microvascular density
- Accelerated arteriolosclerosis: Hyalinization of arterioles from hypertension + uremia reduces vasodilatory reserve
- Phosphate/FGF-23 excess: Elevated FGF-23 (present early in CKD) independently causes LV hypertrophy and CMD via endothelial dysfunction
- Calcium-phosphate deposition: Medial calcification of microvasculature
- Endothelial dysfunction: Reduced eNOS activity, asymmetric dimethylarginine (ADMA) accumulation inhibits NO synthesis
- Autonomic neuropathy (uremic): Impaired coronary vasomotor regulation
CMD Manifestations in CKD
- Reduced Coronary Flow Reserve (CFR < 2.0): Present in up to 50–70% of CKD/ESRD patients even without obstructive CAD
- Increased Index of Microcirculatory Resistance (IMR)
- Microvascular angina: Anginal symptoms with normal epicardial coronaries — common in CKD
- LV hypertrophy + diastolic dysfunction: CMD reduces subendocardial perfusion → fibrosis → diastolic dysfunction (CKD cardiomyopathy)
- Silent ischemia: High prevalence due to autonomic/sensory neuropathy masking symptoms
Hemodialysis Patients
- Intradialytic hypotension causes repeated myocardial stunning via CMD
- Arteriovenous fistula increases cardiac output demand, stressing already dysfunctional microvasculature
- Myocardial hibernation and regional wall motion abnormalities can occur without obstructive CAD
Diagnosis of CMD in Kidney Disease
Non-Invasive
| Test | Finding in CMD | Caveat in CKD |
|---|---|---|
| Stress Echo | Reduced CFR (TTDE Doppler on LAD), regional WMA | Suboptimal windows common |
| PET Myocardial Perfusion Imaging | Reduced absolute myocardial blood flow, CFR < 2.0 | Gold standard; adenosine may be needed |
| Cardiac MRI | Microvascular obstruction, subendocardial perfusion defects | Gadolinium contraindicated in eGFR < 30 (NSF risk) |
| CTCA + CT perfusion | Contrast load concern | Minimize contrast; pre-hydration critical |
Invasive (Cardiac Catheterization)
| Index | Threshold | Interpretation |
|---|---|---|
| CFR (Coronary Flow Reserve) | < 2.0 | CMD present |
| IMR (Index of Microcirculatory Resistance) | > 25 | Structural CMD |
| HMR (Hyperemic Microvascular Resistance) | > 2.5 | Functional CMD |
| RRR (Resistance Reserve Ratio) | < 3.5 | CMD |
Note: Contrast use in catheterization should be minimized in CKD — use iso-osmolar contrast (iodixanol), limit volume (contrast dose/eGFR ratio < 3.0–3.7), and ensure adequate pre-hydration with IV saline or sodium bicarbonate.
Management of CMD in AKI and CKD
General Principles
- Treat the underlying kidney disease — reversing AKI or slowing CKD progression reduces CMD burden
- Aggressive cardiovascular risk factor management: hypertension, dyslipidemia, anemia, hyperphosphatemia
Pharmacological Strategies
| Drug Class | Mechanism | Evidence |
|---|---|---|
| ACE inhibitors / ARBs | Reduce RAAS-driven microvascular remodeling; decrease ADMA | First-line in CKD with proteinuria; caution in bilateral RAS or AKI |
| SGLT2 inhibitors | Reduce inflammation, improve endothelial function, renoprotection | Benefit in CKD (DAPA-CKD, CREDENCE); emerging CMD data |
| Statins | Pleiotropic endothelial effects, reduce oxidative stress | Standard in CKD cardiovascular management |
| Ranolazine | Reduces late INa, improves subendocardial perfusion | Used in microvascular angina; renal dose adjustment needed |
| Nicorandil | K-ATP channel opener; microvascular vasodilation | Used in microvascular angina |
| CCBs (amlodipine) | Microvascular vasodilation | Useful for vasospastic component; safe in CKD |
| Beta-blockers | Reduce demand ischemia | Use with caution in dialysis patients (hemodynamic instability) |
| EPO / ESA | Correct anemia (Hb target 10–11.5 g/dL) | Reduces CMD-related demand ischemia; avoid supranormal Hb |
| Phosphate binders / calcitriol | Reduce FGF-23, vascular calcification | Indirect CMD benefit |
Revascularization
- PCI/CABG for obstructive CAD has limited benefit in advanced CKD (per ISCHEMIA-CKD trial — invasive strategy did not reduce death/MI vs. medical therapy alone at 2.2 years)
- CMD itself is not amenable to revascularization — medical and risk factor optimization is the cornerstone
- Renal transplantation may partially improve CMD by removing the uremic milieu
Key Takeaways
- CMD is highly prevalent in both AKI and CKD and is a major contributor to cardiovascular mortality in these populations
- In AKI, CMD is largely functional/inflammatory and may be reversible with kidney recovery
- In CKD, CMD is structural (capillary rarefaction, fibrosis, calcification) and progressive
- CFR < 2.0 on PET or invasive assessment is the diagnostic benchmark
- Management is medical-first: RAAS blockade, SGLT2i, statins, anemia/phosphate control, and targeted anti-anginal therapy
- ISCHEMIA-CKD trial data confirm revascularization does not improve outcomes over medical therapy in CKD with stable ischemia (Perioperative Cardiovascular Evaluation and Management, p. 68)
This is a shared conversation. Sign in to Orris to start your own chat.